Summary
Objectives
To demonstrate the relationship between adiponectin and insulin resistance among adolescents and young adults
Design
A cross-sectional descriptive study.
Setting
This study was conducted within a tertiary institution and the medical outpatient department (MOPD) of its adjourning tertiary health-care institution.
Participants
The study was conducted among students of a tertiary institution and patients attending the ABUAD Multi-system Hospital, aged 16-24 years.
Main outcome measure
The mean levels of serum adiponectin in obese adolescents and young adults and its relationship with clinical correlates of insulin resistance
Results
Mean serum adiponectin level was 6.8 µg/ml, which is comparable to what has been obtained in other studies. Statistically non-significant negative correlations were noted between serum adiponectin and the homeostasis model assessment of insulin resistance (HOMA-IR), as well as with the clinical correlates of insulin resistance such as Body Mass Index and diastolic blood pressure.
Conclusion
This study demonstrated no significant correlation between serum adiponectin and markers of insulin resistance among these participants and may not be a useful marker of insulin resistance among this group of individuals; hence, its routine measurement may not be appropriate. A follow-up study involving more obese subjects may, however, be more revealing.
Funding
None declared
Keywords: Serum Adiponectin, Obesity, Insulin resistance, Adolescents and Young adults
Introduction
The World Health Organisation (WHO) defines overweight and obesity as abnormal or excessive accumulation of fat that may impair health.1 There has been a steady increase in the prevalence of obesity since the early 1980s, with its attendant complications, and this has posed significant health challenges among the population globally.2
It is a growing healthcare concern worldwide and is an endemic health problem in both developed and developing countries.3 It is associated with many chronic diseases, including hypertension, dyslipidaemia, type 2 diabetes mellitus and some cancers.4 Obesity is a chronic and stigmatising disease that is causally related to serious medical illnesses, impaired quality of life, and considerable economic burden due to increased health care costs and loss of productivity.5
About 12 million people in Nigeria were estimated to be obese in 2020, with prevalence considerably higher among women. Nutritional and epidemiological transitions driven by demographic changes, rising income, urbanisation, unhealthy lifestyles and consumption of highly processed diets appear to be driving an obesity epidemic in the country.6
Adolescent obesity is a public health problem that affects not only physical growth and development, but also has an impact on social and emotional issues and experiences in stigmatising situations.7 They are often victims of these stigmatisations and their obesity results in a wide range of unsolicited psychosocial and medical costs, including impacting adult physique, poor self-esteem and self-image, problems of integration with peers, depression, anxiety and the chronic diseases attributable to excess adiposity.8,9
It has also been established that the pre-diabetes rate in overweight adolescents is 2-6 times higher than that of normal weight adolescents.10 In some countries like the US, close to 1 in 5 adolescents and 1 in 4 young adults are living with prediabetes, the prevalence of which is higher among obese individuals.11 Generally, young adults are often presumed healthy and are therefore rarely the subjects of obesity research (as opposed to children and the elderly).12 Overweight/obesity in adolescents and young adults, if left unchecked, will constitute future risks for associated non-communicable diseases such as diabetes and cardiovascular disease.8,13,14
There is an important relationship between Obesity and Insulin resistance. Suraamornkul et al.15 reported that obesity is associated with increased insulin resistance. Akande et al.16, in a study conducted among the Nigerian population, confirmed a positive correlation between overweight/obesity and insulin resistance.
Obesity associated chronic low-grade inflammation is a major cause of decreased insulin sensitivity, which makes obesity a major risk factor for insulin resistance.17-19 Obesity may increase the expression of certain inflammatory cytokines and activate multiple signalling pathways, both of which contribute to the pathogenesis of insulin resistance by interfering with insulin signalling and action.20
Functionally, adiponectin (a 244-amino-acid-long collagen-like hormone protein, also referred to as AdipoQ) modulates energy metabolism, including glucose and fatty acid oxidation, insulin sensitivity, inflammation, and atherosclerosis, and is the most abundant circulating adipokine secreted by adipose tissue.21
It has also been demonstrated that adiponectin, as an anti-inflammatory marker, inversely correlates with indices of obesity such as waist circumference, BMI and Waist-hipratio (WHR), while pro-inflammatory markers such as hsCRP and IL-6 showed positive correlation with BMI.22 Several studies,23,24 have shown the relevance of serum adiponectin as an anti-inflammatory marker which is usually reduced in obesity, T2DM and other conditions associated with insulin resistance.
This study evaluated the usefulness of adiponectin as a marker of insulin resistance in obese Nigerian adolescents and young adults attending a Tertiary Institution.
Methods
The study was conducted among students of Afe Babalola University of Ado-Ekiti (ABUAD) and patients attending the ABUAD Multi-system Hospital, aged 16-24 years. A simple random sampling method was used in this cross-sectional descriptive study.
Subjects who were known or suspected to have chronic debilitating diseases such as chronic heart failure, chronic liver disease, chronic renal failure, subjects with diabetes mellitus or those who were on long-term steroid therapy, diuretics, beta-blockers, as well as subjects who had acute febrile illness in the preceding week before the study and subjects presenting with diabetic emergencies were all excluded.
Ethical approval was sought for and granted by the University and hospital's Ethics and Research Committee - Research and Ethics Committee, Afe Babalola University, Ado-Ekiti (ABUAD), Nigeria. Reference number: AMSH/REC/OE/046. Written informed consent was also obtained from participants.
The clinical history and relevant examination were obtained and documented. Anthropometry and blood pressure were measured and documented using standard protocols.25,26
Laboratory assessment for all subjects included the collection of 5-7 mL of venous blood sample at once under aseptic procedure from the cubital fossa of each subject between 8.00 and 8.30 a.m. after an overnight fast of at least 8 hours but not more than 12 hours. All subjects were assessed for insulin resistance using the homeostatic model assessment of insulin resistance (HOMA-IR), as described by Matthews et al.27,28. The formula proposed by Matthews et al is:
HOMA-IR = (fasting plasma insulin (µU/ml) × fasting plasma glucose (mmol/l))/22.5
The constant is a normalising factor, the product of fasting plasma insulin of 5µU/mL and plasma glucose of 4.5mmol/L obtained from an “ideal” and “normal” individual. Therefore, for an individual with normal insulin sensitivity, HOMA-IR = 1.
The IR cut-off point in blacks approximates the mean value of 1.95 + 1 standard deviation (SD) (0.1) obtained in Ghanaians with normal FBG and blood pressure using the HOMA model29 Serum adiponectin level was measured using enzyme-linked immunosorbent assay (Elab-science, USA).
Data Analysis/Calculations
The data collected for the study were analysed using the Statistical Package for Social Sciences (SPSS) version 23.0 for Windows (IBM Corp., Armonk, N.Y., USA). Descriptive statistics, such as means and standard deviations, were calculated for the continuous variables (anthropometric parameters, fasting blood glucose, fasting plasma insulin, fasting plasma adiponectin, lipid profiles), while frequencies and percentages were computed for the categorical variables (participants' age and obesity grades). The Pearson correlation technique (Relationship between serum Adiponectin levels and clinical and biochemical correlates of Insulin resistance), independent-samples t-tests, and the F-test (Analysis of variance) were employed for inferential statistics. P-value < 0.05 was considered statistically significant.
Results
A total of 90 participants were involved in the study. The respondents' ages ranged from 16 to 24 years, with a mean age of 19.4 ± 1.7 years. More than half (52.2%) of the respondents belonged to a common age group of 16-19 years, while others (47.8%) were in the age range of 20 to 24 years. Approximately one-third of the study participants were male (32.2%), and the remaining two-thirds (67.8%) were female.
A total of 37.8% of the study participants had a positive recent history of hyperphagia, while almost all the participants (98.9%) admitted to the regular consumption (≥ 3 per week) of calorie-dense foods. The majority of the study participants (63.3%) had a family history of obesity, specifically in their mothers, while 68.9% had a positive family history of obesity in other First-Degree Relatives (FDR). Almost half of the study participants (47.8%) had a positive history of hyperphagia in childhood, while a larger percentage (63.3%) were noted to have had a history of obesity in childhood. (Figure 1) Most participants (87.8%) were not engaged in regular exercise, and more than half (51.1%) reported a history of sedentary behaviour.
Table 1 shows that the mean weight of study participants was 102.7kg, and the mean height was 1.69 m. The mean body mass index (BMI) of the study participants was 35.7kg/m2, with a minimum of 30.0kg/m2 and a maximum of 49.3kg/m2. The mean values for waist circumference and hip circumference were 103.1 cm and 123.7cm, respectively. The mean waist–hip ratio was 0.83, while the mean systolic and diastolic blood pressures were 126mmHg and 84mmHg, respectively.
Table 1.
Clinical examination findings of Study participants
| Mean | SEM | Std. Dev. | Minimum | Maximum | |
|---|---|---|---|---|---|
| Weight (kg) | 102.79 | 1.78 | 16.89 | 74.0 | 148.0 |
| Height (metres) | 1.69 | 0.01 | 0.09 | 1.53 | 1.91 |
| Body mass Index (kg/m2) | 35.75 | 0.52 | 4.91 | 30.0 | 49.3 |
| Waist circumference (cm) | 103.1 | 1.33 | 12.64 | 77.0 | 141.0 |
| Hip circumference (cm) | 123.79 | 0.99 | 9.39 | 104.0 | 156.0 |
| Waist-Hip-ratio (WHR) | 0.83 | 0.009 | 0.09 | 0.66 | 1.14 |
| Systolic Blood Pressure | 126.37 | 1.46 | 13.82 | 90.0 | 156.0 |
| Diastolic Blood Pressure | 84.41 | 1.25 | 11.86 | 53.0 | 106.0 |
SEM: standard error of mean; Std. Dev.: standard deviation
More than half (54%) of the study participants had grade 1 obesity, while 28% had grade 2 obesity, and morbid obesity was noted in 18% of the subjects. The majority of the study participants (87%) were obese by both Body mass index and waist circumference measurements, while 13% were observed to be obese with only their BMI.
Table 2 shows that the mean fasting blood glucose was 4.86 mmol/L among the study participants. Mean fasting plasma insulin levels were 2.95 µIU/ml, while the mean fasting adiponectin levels were 6.8µg/ml. The mean HOMA-IR was noted to be 0.64
Table 2.
Laboratory results of study participants
| Mean | SEM | Std. Dev. | Minimum | Maximum | |
|---|---|---|---|---|---|
| Fasting Blood Glucose | 4.86 | 0.11 | 1.08 | 3.57 | 13.65 |
| Fasting Plasma Insulin Level | 2.95 | 0.1 | 0.9 | 1.69 | 7.22 |
| Fasting Plasma Adiponectin Level | 6.82 | 0.46 | 4.4 | 1.61 | 22.46 |
| High-Density Lipoprotein - Cholesterol | 1.4 | 0.03 | 0.33 | 0.76 | 2.8 |
| Triglyceride | 1.09 | 0.12 | 1.12 | 0.38 | 9.81 |
| Low-Density Lipoprotein - Cholesterol | 2.62 | 0.08 | 0.75 | 0.80 | 6.14 |
| Total Cholesterol | 4.54 | 0.09 | 0.90 | 3.00 | 8.59 |
| HOMA – IR | 0.64 | 0.03 | 0.25 | 0.29 | 2.02 |
SEM: standard error of mean; Std. Dev.: standard deviation
The mean serum adiponectin levels were significantly higher in females than in males (p=0.032). Similarly, serum adiponectin was higher in the younger age group (16-19) than in the older age group (20-24); however, this difference was not statistically significant, and there was no significant association between serum adiponectin and obesity class. (Table 3)
Table 3.
Mean levels of serum adiponectin by sex, age and body mass index
| Mean | SD | SEM | Minimum | Maximum | p-value | |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 6.14 | 3.37 | 0.43 | 1.61 | 18.72 | 0.03* |
| Female | 8.25 | 5.84 | 1.08 | 1.64 | 22.49 | |
| Total | 6.82 | 4.4 | 0.46 | 1.61 | 22.49 | |
| Age | ||||||
| 16-19 | 7.4 | 5.09 | 0.74 | 1.64 | 22.49 | 0.19 |
| 20-24 | 6.18 | 3.44 | 0.52 | 1.61 | 14.47 | |
| Total | 6.82 | 4.4 | 0.46 | 1.61 | 22.49 | |
| BMI | ||||||
| Grade 1 | 6.86 | 4.04 | 0.58 | 1.64 | 22.3 | 0.798 |
| Grade 2 | 7.13 | 5.68 | 1.14 | 1.61 | 22.49 | |
| Morbid | 6.19 | 3.21 | 0.8 | 1.66 | 12.11 | |
| Total | 6.82 | 4.4 | 0.46 | 1.61 | 22.49 |
P-value <0.05
The linear relationship between serum adiponectin and clinical correlates of insulin resistance, such as WC, WHR, BMI, SBP, and DBP, was assessed using Pearson's Correlation in Table 4.
Table 4.
Relationship between serum adiponectin levels and clinical and biochemical correlates of Insulin resistance
| R | p-value | |
|---|---|---|
| Body mass Index (kg/m2) | -0.06 | 0.596 |
| Waist circumference (cm) | 0.08 | 0.449 |
| Hip circumference (cm) | 0.10 | 0.34 |
| Waist-Hip-ratio (WHR) | 0.10 | 0.354 |
| Systolic Blood Pressure | 0.11 | 0.294 |
| Diastolic Blood Pressure | -0.03 | 0.761 |
| HOMA – IR | -0.19 | 0.075 |
r: Pearson Correlation coefficient; *: P-value <0.05
There was a negative correlation between serum adiponectin and body mass index, diastolic blood pressure, and HOMA-IR; however, this was not statistically significant. In contrast, there was a non-significant positive correlation between serum adiponectin and waist circumference, hip circumference, waist-to-hip ratio, and systolic blood pressure.
Discussion
Serum adiponectin levels have been associated with correlates of insulin resistance, such as HOMA-IR, waist circumference, BMI, and lipid profile, among obese adolescents and young adults. Some studies have shown that this adipocytokine, with its anti-inflammatory and anti-atherogenic properties, may be a useful biomarker of obesity and predictive index of insulin resistance in these patients.30 Some other studies done in Africans, however, did not establish such a relationship.31 This study comprised 90 obese adolescents and young adults.
In this study, obesity was determined using both Body mass index (BMI) and waist circumference. The BMI is widely recognised as a useful and effective tool for the determination and subclassification of obesity among adolescents and young adults.32 In addition to the BMI, the National Institute of Health (NIH) also recognises waist circumference as a tool by which abdominal obesity can be measured, as this is noted to correlate better with insulin resistance.33
The age range of subjects in this study was from 16 to 24 years, and more than half of the study population (52.2%) were in the 16-19 age bracket, while 47.8% of participants were in the 20-24 years age bracket, with the mean age of the study population being 19.4years ± 1.7.
It is worth noting that since the participants are from a single institution and include both students and patients, they may not accurately represent the general adolescent or young adult population in Nigeria.
Almost all the study participants (98.9%) had a positive history of regular consumption (≥ 3 per week) of calorie–dense foods such as pastries, egg yolk, red meat, pizza, fizzy drinks, etc., and about 37.8% of the participants also had a recent history of eating excessively. Some studies have related the lifestyle of youths to risk factors for obesity, including excess energy consumption as well as excessive eating.34,35
The greatest obesogenic environmental risk is diet; the high caloric, overly processed, and poor quality of certain diets have increased genetic and epigenetic obesity risk and rendered people overfed and undernourished.36 Family history of obesity in the mother or other first-degree relatives was found in 63.3% and 68.9% of study participants, respectively. 63.3% of participants also had a history of obesity in childhood. The risk of becoming an obese adult is increased both by having been obese as a child and by having at least one obese parent. The risk of adult obesity rises with increasing age and with the severity of obesity in childhood. For example, the risk of being obese at 21 to 29 years of age ranged from 8% for persons who were obese at 1 to 2 years of age and had non-obese parents to 79% for persons who were obese at 10 to 14 years of age and had at least one obese parent. Although persons who were obese at 1 to 2 years of age and had lean parents did not have an increased risk of obesity in adulthood, persons who became obese after 6 years of age had a greater than 50% chance of becoming obese adults.37
The mean serum adiponectin level in the study participants was 6.82 µg/ml, with a minimum of 1.61 µg/ml and a maximum of 22.46 µg/ml. In a study done among Indian adolescents by Jain et al in 2017.38 Similar mean values of serum adiponectin (6.0 µg/ml) were observed. Nri Ezedi et al, however, found a lower mean serum adiponectin in their study among prepubertal Nigerians; the lower level of adiponectin obtained in their study may not be unconnected with the younger age of their study population compared with our study39
The mean serum adiponectin was significantly higher among the female subjects (8.25µg/ml), than their male counterparts (6.14µg/ml) (p=0.032). This is attributable to differences in body adiposity between the sexes, and various studies have shown that sex hormones also affect the production rate of adiponectin.40,41
Serum adiponectin levels by age group were comparable, with subjects aged 16–19 years having a mean adiponectin level of 7.4 µg/ml, whereas those aged 20–24 years had a mean of 6.18 µg/ml. The age gap between these groups apparently did not make much of a difference, though it has been noted that circulating levels of Adiponectin are influenced by age.42,43
According to BMI, the mean serum adiponectin levels for grade 1 obese subjects were 6.86 µg/ml, whereas those for subjects with grades 2 and 3 obesity were 7.13 µg/ml and 6.82 µg/ml, respectively. These differences in adiponectin values, however, were not statistically significant. In various studies done, BMI has been found to correlate with adiponectin levels in young adults.44,45
The HOMA-IR is a surrogate marker of insulin resistance and was used in this study to assess the relationship between serum adiponectin and insulin resistance. Waist circumference (WC), Body mass Index (BMI), waist–to–hip ratio (WHR), systolic and diastolic blood pressure, are not only clinical, anthropometric, and laboratory parameters but also markers of insulin resistance and were used in this study as clinical and biochemical correlates of insulin resistance. In this study, Serum adiponectin levels correlated negatively with Body mass index (r =-0.06, p = 0.596) and HOMA-IR (r = -0.19, p = 0.075), though not statistically significant and positively with waist circumference (r = 0.08, p = 0.449), hip circumference (r = 0.10, p = 0.34), waist-hip ratio (r = 0.10, p = 0.354), and Systolic blood pressure (r = 0.11, p = 0.294),; however, these were also not statistically significant. The above were all weakly positive and negative correlations. Similar findings from certain studies have demonstrated a relationship between adiponectin and Body mass index, as well as HOMA-IR and waist circumference as markers of obesity and insulin resistance.
In a study by Varda et al. 30 on obese Slovenian adolescents, adiponectin showed a strong, statistically significant negative correlation with BMI across all three observed groups (p < 0.001). It was therefore concluded that adiponectin and other obesity-related biological markers tested (ghrelin & leptin) are useful early markers for identifying patient groups at cardiovascular risk.
A similar observation was made by Khabour et al44 in a study done among obese female Jordanian young adults, where it was demonstrated that adiponectin and BMI correlated negatively. However, further comparisons showed BMI or adiponectin were not related to G276T and I164T Single Nucleotide Polymorphisms (SNP) of the ADIPOQ gene in these young adult women.
These are contrary to findings by Hassan et al31 who studied Egyptian obese adolescents and observed a poor correlation between adiponectin and BMI, HOMA-IR, and WC and therefore concluded that there was no direct link between these parameters. The authors were of the notion that what applies to other ethnic populations might not apply to the African population. Racial differences, as proposed by these authors, as well as Lee et al in 2006,46 who had similar findings in their study, which was between African Americans and their Caucasian peers, may be largely responsible for these variations. The above relationship between adiponectin and other variables, showing weak and non-significant correlations, underscores the need for further, larger cohort studies.
This study has some limitations. The study setting did not allow for generalisation of our findings to all other adolescents and young adults in Nigeria, given that only one institution was studied. However, a one-centre study, despite its limitations, provides a basis for future multicentre studies. The relatively small sample size and cross-sectional nature preclude adequate causal inference. However, the study's findings contribute to the limited body of research in this field in our environment.
Body mass index (BMI) was used to assess obesity in this study. While widely used to evaluate obesity, this method has limitations, including its inability to predict the degree of adiposity in patients. Assessing other biologic markers of obesity and insulin resistance, such as Leptin, Ghrelin, and Tumour necrosis factor alpha, would have enhanced the findings in this study, but this could not be done due to the huge cost that would be involved and the lack of laboratory facilities for the assay of some of the biomarkers.
Conclusion
Serum adiponectin was not associated with HOMA-IR or other clinical correlates of insulin resistance, such as Body mass index and diastolic blood pressure (DBP). However, as expected, there was a negative correlation with these parameters. Other clinical correlates, such as waist circumference, hip circumference, waist-to-hip ratio (WHR), and systolic blood pressure (SBP), showed positive correlations but were not statistically significant. All the above exploratory findings, however, were weakly positive or negative.
Routine measurement of serum adiponectin may have limited utility as a sole marker of insulin resistance among obese adolescents and young adults in our environment. However, further studies with larger sample sizes and diverse populations are needed to validate the findings from this research.
Acknowledgement
Special appreciation goes to the entire members and staff of the Physiology and Medicine departments of Afe Babalola University for their support and technical assistance during the conduct of the study—special thanks also to Professor J.O. Sanya and Professor R.O. Akomolafe for their extensive review of the manuscript.
References
- 1.World Health Organization, author. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. 2022. [29 December, 2024]. Available online: https://iris.who.int/handle/10665/42330 . [PubMed]
- 2.Inoue Y, Qin B, Poti J, et al. Epidemiology of Obesity in Adults: Latest Trends. Curr Obes Rep. 2018;7:276–288. doi: 10.1007/s13679-018-0317-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bhurosy T, Jeewon R. Overweight and obesity epidemic in developing countries: a problem with diet, physical activity, or socioeconomic status? Scientific World Journal. 2014;2014:964236. doi: 10.1155/2014/964236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab. 2010;12(11):941–946. doi: 10.1111/j.1463-1326.2010.01256.x. [DOI] [PubMed] [Google Scholar]
- 5.Lehnert T, Sonntag D, Konnopka A, Riedel-Heller S, König HH. Economic costs of overweight and obesity. Best Pract Res Clin Endocrinol Metab. 2013;27(2):105–115. doi: 10.1016/j.beem.2013.01.002. [DOI] [PubMed] [Google Scholar]
- 6.Adeloye D, Ige-Elegbede JO, Ezejimofor M, Owolabi EO, Ezeigwe N, Omoyele C, Mpazanje RG, Dewan MT, Agogo E, Gadanya MA, Alemu W, Harhay MO, Auta A, Adebiyi AO. Estimating the prevalence of overweight and obesity in Nigeria in 2020: a systematic review and meta-analysis. Ann Med. 2021;53(1):495–507. doi: 10.1080/07853890.2021.1897665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kansra AR, Lakkunarajah S, Jay MS. Childhood and Adolescent Obesity: A Review. Front Pediatr. 2021;8:581461. doi: 10.3389/fped.2020.581461. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ejike CE. Child and adolescent obesity in Nigeria: A narrative review of prevalence data from three decades (1983-2013) Journal of Obesity and Metabolic Research. 2014;1:171. [Google Scholar]
- 9.Lazzeri G, Rossi S, Pammolli A, Pilato V, Pozzi T, Giacchi MV. Underweight and overweight among children and adolescents in Tuscany (Italy). Prevalence and short-term trends. J Prev Med Hyg. 2008;49(1):13–21. [PubMed] [Google Scholar]
- 10.Li C, Ford ES, Zhao G, Mokdad AH. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005-2006. Diabetes Care. 2009;32(2):342–347. doi: 10.2337/dc08-1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016. JAMA Pediatr. 2020;174(2):e194498. doi: 10.1001/jamapediatrics.2019.4498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ejike CE, Ijeh II. Obesity in young-adult Nigerians: variations in prevalence determined by anthropometry and bioelectrical impedance analysis, and the development of % body fat prediction equations. Int Arch Med. 2012;5(1):22. doi: 10.1186/1755-7682-5-22. Published 2012 Jul 20. http://doi.10.1186/1755-7682-5-22 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ukegbu PO, Uwaegbute AC, Echendu CA, Ejike CE, Anyika-Elekeh JU, Asumugha VU, Kuyik SA, Omodamiro S, Nwofia B, Uzokwe CA, Oluchi-Nliam C, Uwakwe N. Obesity and associated factors in young adults attending tertiary institutions in south-eastern Nigeria. South African Journal of Clinical Nutrition. 2017;30:43–48. doi: 10.1080/16070658.2016.1259032. [DOI] [Google Scholar]
- 14.Yusuf SM, Mijinyawa MS, Musa BM, Gezawa ID, Uloko AE. Overweight and Obesity among Adolescents in Kano, Nigeria. J Metabolic Synd. 2013;2:126. doi: 10.4172/2167-0943.1000126. [DOI] [Google Scholar]
- 15.Suraamornkul S, Kwancharoen R, Ovartlarnporn M, Rawdaree P, Bajaj M. Insulin clamp-derived measurements of insulin sensitivity and insulin secretion in lean and obese Asian type 2 diabetic patients. Metab Syndr Relat Disord. 2010;8(2):113–118. doi: 10.1089/met.2009.0030. [DOI] [PubMed] [Google Scholar]
- 16.Akande TO, Adeleye JO, Kadiri S. Insulin resistance in Nigerians with essential hypertension. Afr Health Sci. 2013;13(3):655–660. doi: 10.4314/ahs.v13i3.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mohanraj L, Kim HS, Li W, et al. IGFBP-3 inhibits cytokine-induced insulin resistance and early manifestations of atherosclerosis. PLoS One. 2013;8(1):e55084. doi: 10.1371/journal.pone.0055084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Daniele G, Guardado Mendoza R, Winnier D, et al. The inflammatory status score including IL-6, TNF-a, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2014;51(1):123–131. doi: 10.1007/s00592-013-0543-1. [DOI] [PubMed] [Google Scholar]
- 19.Osborn O, Olefsky JM. The cellular and signalling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363–374. doi: 10.1038/nm.2627. [DOI] [PubMed] [Google Scholar]
- 20.Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–2180. doi: 10.1053/j.gastro.2007.03.059. [DOI] [PubMed] [Google Scholar]
- 21.Fang H, Judd RL. Adiponectin Regulation and Function. Compr Physiol. 2018;8(3):1031–1063. doi: 10.1002/cphy.c170046. Published 2018 Jun 18. [DOI] [PubMed] [Google Scholar]
- 22.Jain V, Kumar A, Agarwala A, Vikram N, Ramakrishnan L. Adiponectin, Interleukin-6 and High-sensitivity C-reactive Protein Levels in Overweight/Obese Indian children. Indian Pediatr. 2017;54(10):848–850. doi: 10.1007/s13312-017-1148-5. [DOI] [PubMed] [Google Scholar]
- 1.
- 23.Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52(2):239–243. doi: 10.2337/diabetes.52.2.239. [DOI] [PubMed] [Google Scholar]
- 24.Winer JC, Zern TL, Taksali SE, et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(11):4415–4423. doi: 10.1210/jc.2006-0733. [DOI] [PubMed] [Google Scholar]
- 25.World Health Organization, author. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. Geneva: World Heal Organ; 2011. [Google Scholar]
- 26.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee, author. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560–2572. doi: 10.1001/2003/12748199. [DOI] [PubMed] [Google Scholar]
- 27.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi: 10.1007/BF00280883. [DOI] [PubMed] [Google Scholar]
- 28.Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, Haghazali M, Asgari F. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance risk factors of non-communicable diseases in Iran (SuRFNCD-2007) Nutr Metab. 2010;7:26. doi: 10.1186/1743-7075-7-26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Amoah AG, Schuster DP, Gaillard T, Osei K. Insulin sensitivity and cardiovascular risk factors in hypertensive and normotensive native Ghanaians. Diabetologia. 2003;46(7):949–955. doi: 10.1007/s00125-003-1130-8. [DOI] [PubMed] [Google Scholar]
- 30.Varda NM, Medved M, Ojsteršek L. The associations between some biological markers, obesity, and cardiovascular risk in Slovenian children and adolescents. BMC Pediatr. 2020;20(1):81. doi: 10.1186/s12887-020-1978-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Hassan NE, EL-Ashry HH, Awad AH, El-Masry SA, Youssef MM, Sallam M, Anwar M. Adiponectin in obese children and its association with blood pressure and anthropometric markers. Med Res J. 2011;10(1):1–4. [Google Scholar]
- 32.Zierle-Ghosh A, Jan A. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Nov 5, Physiology, Body Mass Index. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535456/ [PubMed] [Google Scholar]
- 33.NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US), author Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998. Sep, Executive Summary. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2008/ [Google Scholar]
- 34.Kerkadi A, Sadig AH, Bawadi H, et al. The Relationship between Lifestyle Factors and Obesity Indices among Adolescents in Qatar. Int J Environ Res Public Health. 2019;16(22):4428. doi: 10.3390/ijerph16224428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Lee KX, Quek KF, Ramadas A. Dietary and Lifestyle Risk Factors of Obesity Among Young Adults: A Scoping Review of Observational Studies. Curr Nutr Rep. 2023;12:733–743. doi: 10.1007/s13668-023-00513-9. [DOI] [PubMed] [Google Scholar]
- 36.Brandkvist Maria, Bjørngaard Johan Håkon, Ødegård Rønnaug Astri, Åsvold Bjørn Olav, Sund Erik R, Vie Gunnhild Åberge. Quantifying the impact of genes on body mass index during the obesity epidemic: longitudinal findings from the HUNT Study. BMJ. 2019. p. 366. [DOI] [PMC free article] [PubMed]
- 37.Juonala M, Magnussen C G, Berenson G S, Venn A, Burns T L, Sabin M A, Srinivasan S R, Daniels S R, Davis P H, Chen W, Sun C, Cheung M, Viikari J S, Dwyer T, Raitakari O T. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365(20):1876–1885. doi: 10.1056/NEJMoa1010112. [DOI] [PubMed] [Google Scholar]
- 38.Jain V, Kumar A, Agarwala A, Vikram N, Ramakrishnan L. Adiponectin, Interleukin-6 and High-sensitivity C-reactive Protein Levels in Overweight/Obese Indian children. Indian Pediatr. 2017;54(10):848–850. doi: 10.1007/s13312-017-1148-5. [DOI] [PubMed] [Google Scholar]
- 39.Nri-Ezedi C A, Ulasi T, Chukwuka J, Okpara H, Ofiaeli O, Nwaneli E, Ulasi A. Serum total adiponectin in healthy pre-pubertal Nigerian school children. Niger J Clin Pract. 2021;24(6):821–827. doi: 10.4103/njcp.njcp_427_20. [DOI] [PubMed] [Google Scholar]
- 40.Ohman-Hanson R A, Cree-Green M, Kelsey M M, Bessesen D H, Sharp T A, Pyle L, Pereira R I, Nadeau K J. Ethnic and Sex Differences in Adiponectin: From Childhood to Adulthood. J Clin Endocrinol Metab. 2016;101(12):4808–4815. doi: 10.1210/jc.2016-1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Gavin KM, Bessesen DH. Sex Differences in Adipose Tissue Function. Endocrinol Metab Clin North Am. 2020;49(2):215–228. doi: 10.1016/j.ecl.2020.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Meshkini M, Alaei-Shahmiri F, Mamotte C, Dantas J. Ethnic Variations in Adiponectin Levels and Its Association with Age, Gender, Body Composition and Diet: Differences Between Iranians, Indians and Europeans Living in Australia. J Immigr Minor Health. 2018;20(6):1362–1372. doi: 10.1007/s10903-018-0706-9. [DOI] [PubMed] [Google Scholar]
- 43.Song HJ, Oh S, Quan S, et al. Gender differences in adiponectin levels and body composition in older adults: Hallym aging study. BMC Geriatr. 2014;14(8) doi: 10.1186/1471-2318-14-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Khabour OF, Alomari MA, Abu Obaid AA. The Relationship of adiponectin level and ADI-POQ gene variants with BMI among young adult women. Dermatoendocrinol. 2018;10(1):e1477902. doi: 10.1080/19381980.2018.1477902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Galler A, Gelbrich G, Kratzsch J, Noack N, Kapellen T, Kiess W. Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur J Endocrinol. 2007;157(4):481–489. doi: 10.1530/EJE-07-0250. [DOI] [PubMed] [Google Scholar]
- 46.Lee S, Bacha F, Gungor N, Arslanian SA. Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care. 2006;29(1):51–56. doi: 10.2337/diacare.29.1.51. [DOI] [PubMed] [Google Scholar]
